Cumberland Pharmaceuticals (NASDAQ:CPIX) announced its earnings results on Tuesday, March 6th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, Bloomberg Earnings reports. Cumberland Pharmaceuticals had a negative net margin of 19.39% and a negative return on equity of 1.55%. The business had revenue of $11.65 million for the quarter.
Shares of CPIX stock traded up $0.08 during midday trading on Wednesday, hitting $6.78. The company had a trading volume of 3,207 shares, compared to its average volume of 17,884. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.50 and a current ratio of 3.88. Cumberland Pharmaceuticals has a twelve month low of $5.39 and a twelve month high of $7.96.
Separately, ValuEngine cut Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/21/cumberland-pharmaceuticals-cpix-announces-earnings-results.html.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.